Arcturus Therapeutics Holdings Inc. (ARCT): History, Ownership, Mission, How It Works & Makes Money

Ever wondered how Arcturus Therapeutics Holdings Inc. (ARCT) navigates the complex world of mRNA therapeutics, especially considering its reported Q3 2024 revenues reaching approximately $15.5 million amid critical advancements in its vaccine pipeline? This clinical-stage company focuses squarely on developing messenger RNA medicines, tackling infectious diseases and rare liver conditions with innovative self-amplifying mRNA technology. With significant partnerships shaping its path forward, understanding ARCT's journey, ownership structure, and core mission becomes crucial. Ready to explore how this biotech translates scientific potential into tangible business operations and revenue?

Arcturus Therapeutics Holdings Inc. (ARCT) History

Understanding where a company comes from is crucial to evaluating its future potential. Let's look back at the key moments that shaped Arcturus Therapeutics.

Arcturus Therapeutics Holdings Inc.'s Founding Timeline

Year established

2013

Original location

San Diego, California, USA

Founding team members

Joseph Payne and Pad Chivukula founded the company, bringing expertise in nucleic acid chemistry and drug delivery.

Initial capital/funding

The company secured initial seed funding followed by a Series A round raising approximately $5 million in late 2013, enabling early research and development activities focused on RNA therapeutics.

Arcturus Therapeutics Holdings Inc.'s Evolution Milestones

Arcturus Therapeutics Holdings Inc.'s Transformative Moments

Going Public via Reverse Merger (2017)

This strategic move provided vital access to public funding, enabling the company to advance its multiple R&D programs without relying solely on venture capital or dilutive partnerships at early stages. It was a necessary step for long-term clinical development ambitions.

Validation and Expansion of LUNAR® Platform Partnerships

Securing deals with major players like Janssen, Ultragenyx, and especially the large-scale CSL Seqirus collaboration demonstrated the LUNAR® delivery system's value and versatility across different therapeutic areas, significantly de-risking the technology in the eyes of the market and investors. Exploring Arcturus Therapeutics Holdings Inc. (ARCT) Investor Profile: Who’s Buying and Why? offers more detail on how these partnerships influenced investor interest.

Rapid COVID-19 Vaccine Development and Approval (2020-2023)

The company's ability to quickly pivot and leverage its mRNA technology during the pandemic, leading to clinical trials, major funding (BARDA, Vinbiocare), the CSL partnership, and ultimately regulatory approval in Japan, was a defining period. It showcased execution capability and transformed Arcturus into a recognized player in the mRNA space.

Arcturus Therapeutics Holdings Inc. (ARCT) Ownership Structure

Arcturus Therapeutics Holdings Inc. operates as a publicly traded entity, meaning its shares are available for purchase by the general public on the stock exchange. Consequently, its ownership is dispersed among various groups, including large institutional investors, company insiders, and individual retail shareholders.

Arcturus Therapeutics Holdings Inc.'s Current Status

As of the end of 2024, Arcturus Therapeutics Holdings Inc. is a publicly traded company listed on the NASDAQ Global Select Market under the ticker symbol ARCT. This status makes its shares accessible to a wide range of investors and subjects the company to regulatory oversight and reporting requirements mandated by the Securities and Exchange Commission (SEC). Understanding its public nature is crucial when analyzing its governance and potential market influences. For deeper insights, consider Breaking Down Arcturus Therapeutics Holdings Inc. (ARCT) Financial Health: Key Insights for Investors.

Arcturus Therapeutics Holdings Inc.'s Ownership Breakdown

The ownership structure provides insight into who holds significant influence over the company. Based on filings towards the end of 2024, the distribution is primarily concentrated among institutional holders.

Note: These percentages are approximate based on publicly available data towards the end of 2024 and can fluctuate.

Arcturus Therapeutics Holdings Inc.'s Leadership

Steering the company's strategic direction and operations at the close of 2024 is a dedicated executive team. Key figures guiding Arcturus Therapeutics include:

• Joseph Payne: President and Chief Executive Officer
• Dr. Padmanabh Chivukula: Chief Scientific Officer and Chief Operating Officer
• Andrew Sassine: Chief Financial Officer

This leadership team brings extensive experience in biotechnology and pharmaceuticals, responsible for executing the company's mission and driving innovation in mRNA medicines.

Arcturus Therapeutics Holdings Inc. (ARCT) Mission and Values

Arcturus Therapeutics Holdings Inc. anchors its strategic direction and corporate culture in a distinct mission focused on pioneering RNA-based medicines. These guiding principles shape its research priorities and operational conduct, offering a glimpse into the company's aspirations beyond pure financial metrics.

Arcturus Therapeutics Holdings Inc. (ARCT) Core Purpose

Official mission statement

The company is dedicated to the discovery, development, and commercialization of breakthrough RNA medicines. Arcturus specifically targets rare genetic disorders, infectious diseases, and other conditions with significant unmet medical needs, leveraging its proprietary technology platforms to create novel therapeutic options. You can gain further insights by Breaking Down Arcturus Therapeutics Holdings Inc. (ARCT) Financial Health: Key Insights for Investors.

Vision statement

While not always articulated as a separate formal statement, the overarching vision for Arcturus appears to be establishing itself as a premier global entity in the field of mRNA therapeutics. Their ambition involves significantly impacting patient outcomes worldwide through the successful application of their LUNAR® delivery and STARR™ self-amplifying mRNA technologies.

Company slogan

Arcturus Therapeutics does not seem to employ a specific, consistently used public slogan as part of its primary branding efforts.

Core Values Guiding Operations

The day-to-day operations and long-term strategy at Arcturus are influenced by a set of core values. These values are fundamental to their scientific and business approach.

• Innovation: Continuously pushing the boundaries of RNA science and technology.
• Patient-Centricity: Keeping the needs and well-being of patients at the forefront of all development efforts.
• Integrity: Operating with transparency and maintaining the highest ethical standards.
• Collaboration: Fostering strong partnerships internally and externally to accelerate progress.
• Urgency: Acting decisively and efficiently to bring potentially life-changing therapies to patients as quickly as possible.

Arcturus Therapeutics Holdings Inc. (ARCT) How It Works

Arcturus Therapeutics operates as a clinical-stage messenger RNA (mRNA) medicines company focused on the discovery, development, and commercialization of therapeutics for rare diseases and vaccines. It leverages its proprietary technologies to create RNA medicines designed to address specific diseases by instructing the body's own cells to produce therapeutic proteins or antigens.

Arcturus Therapeutics Holdings Inc.'s Product/Service Portfolio

Arcturus Therapeutics Holdings Inc.'s Operational Framework

The company's operations center around intensive research and development activities focused on its mRNA platforms. This involves preclinical research, candidate selection, and advancing programs through rigorous clinical trials (Phase 1, 2, and 3) to establish safety and efficacy. Arcturus relies heavily on strategic collaborations and licensing agreements with larger pharmaceutical companies, like CSL Seqirus, for late-stage development, manufacturing scale-up, regulatory submissions, and commercialization. These partnerships are crucial for funding ongoing operations and bringing products to market, aligning with the Mission Statement, Vision, & Core Values of Arcturus Therapeutics Holdings Inc. (ARCT). As of late 2024, revenue generation primarily stems from these collaborations, including upfront payments, milestone payments contingent on development progress, and potential future royalties, rather than direct product sales. For the nine months ending September 30, 2024, collaboration revenues were reported at approximately $66.5 million, while research and development expenses, reflecting the focus on pipeline advancement, were around $175.8 million during the same period.

Arcturus Therapeutics Holdings Inc.'s Strategic Advantages

Arcturus possesses several key strategic advantages that underpin its position in the competitive biotech landscape.

• Proprietary Technology Platforms: The STARR™ self-amplifying mRNA technology potentially allows for lower dosage levels compared to conventional mRNA, and the LUNAR® lipid-mediated nanoparticle delivery system enables efficient delivery of RNA payloads to target cells.
• Strategic Partnerships: Collaborations, notably with CSL Seqirus for its COVID-19 vaccine program, provide significant non-dilutive funding, validation, and pathways to commercialization, leveraging partners' global infrastructure and expertise.
• Diverse Pipeline Focus: Targeting both infectious diseases (vaccines) and rare genetic disorders (therapeutics) diversifies risk and expands market opportunities across different therapeutic areas with unmet needs.
• Experienced Leadership: Management team with experience in drug development, mRNA technology, and navigating the regulatory landscape.

Arcturus Therapeutics Holdings Inc. (ARCT) How It Makes Money

Arcturus Therapeutics generates revenue primarily through collaborative agreements with larger pharmaceutical companies for the development and potential commercialization of its mRNA-based therapeutics and vaccines. These agreements often involve upfront payments, milestone payments tied to development progress, and potential future royalties on product sales.

Arcturus Therapeutics Holdings Inc.'s Revenue Breakdown

Based on financial data leading into late 2024, the company's revenue streams are concentrated, reflecting its stage as a clinical development biopharmaceutical company.

Arcturus Therapeutics Holdings Inc.'s Business Economics

The economic engine of the company is heavily weighted towards research and development (R&D). Significant investment is required to advance drug candidates through preclinical studies and multi-phase clinical trials. Key economic factors include:

• High R&D Investment: The largest operational expense, necessary for progressing the pipeline.
• Collaboration Dependency: Near-term revenue heavily relies on achieving milestones within existing partnerships (like CSL Seqirus, BARDA) and securing new ones.
• Long Development Cycles: Bringing a therapeutic from concept to market takes many years and substantial capital, impacting cash flow significantly.
• Potential Future Profitability: Long-term success hinges on regulatory approval and successful commercialization of its LUNAR® platform-based candidates, leading to product sales or larger royalty streams.

Arcturus Therapeutics Holdings Inc.'s Financial Performance

As of late 2024, the company operates with significant R&D expenditures leading to net losses, which is typical for clinical-stage biotech firms. Trailing twelve months (TTM) revenue ending Q3 2024 was approximately $13.1 million, primarily from collaborations. R&D expenses over the same period were substantial, roughly $190 million, contributing to a net loss of around $200 million. The company maintained a cash and equivalents balance of $321.2 million at the end of the third quarter of 2024, crucial for funding ongoing operations and clinical trials. Assessing the company's path forward involves understanding these figures; you can find more details here: Breaking Down Arcturus Therapeutics Holdings Inc. (ARCT) Financial Health: Key Insights for Investors. Financial health is closely tied to clinical trial progress and the ability to manage cash burn effectively until potential product commercialization or further lucrative partnerships materialize.

Arcturus Therapeutics Holdings Inc. (ARCT) Market Position & Future Outlook

Arcturus Therapeutics operates as a clinical-stage messenger RNA medicines company focused on the discovery, development, and commercialization of therapeutics for rare diseases and vaccines, navigating a dynamic landscape dominated by larger players. Its future hinges significantly on the successful clinical progression and potential regulatory approval of its pipeline candidates, particularly its self-amplifying mRNA technology platform, aligning with its core objectives detailed in the Mission Statement, Vision, & Core Values of Arcturus Therapeutics Holdings Inc. (ARCT).

Competitive Landscape

Opportunities & Challenges

Industry Position

Within the burgeoning field of mRNA therapeutics, Arcturus Therapeutics is positioned as an innovator, primarily differentiated by its self-amplifying RNA technology. While not yet possessing the market presence or revenue scale of giants like Moderna or BioNTech/Pfizer, its focus on specific applications, including rare diseases and potentially improved vaccine profiles, carves out a distinct niche. The company's standing heavily relies on demonstrating clinical efficacy and safety advantages through its ongoing trials. Success is deeply intertwined with its ability to secure continued funding, navigate the complex regulatory environment, and leverage its strategic partnerships effectively to bring its novel technology platform from development to market, thereby challenging the established players in targeted segments. Its cash runway, supported by existing funds ($361.4 million as of Sep 30, 2023) and collaboration revenues, is critical for sustaining operations through key clinical milestones expected in 2024 and 2025.